CTOs on the Move

Salk Institute

www.salk.edu

 
Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology, and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature, and fearless in the face of any challenge.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.salk.edu
  • 10010 North Torrey Pines Road
    La Jolla, CA USA 92037
  • Phone: 858.453.4100

Executives

Name Title Contact Details
Michael Austin
Director of Information Technology Profile
Jerry Sheehan
Chief Information Officer Profile

Funding

Salk Institute raised $25M on 11/21/2016
Salk Institute raised $14.3M on 10/23/2019

Similar Companies

Cytonome

Cytonome is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio Essence Corp

Bio Essence Corp is a Richmond, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Defyrus

Defyrus Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Luzsana Biotechnology

Luzsana Biotechnology™ is a new kind of biotech company with a mission to make innovative medicines available, accessible, and affordable to anyone, anywhere.

Chiasma

Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.